Study shows checkpoint inhibitor prolongs survival in patients with certain head and neck cancers
The checkpoint inhibitor pembrolizumab (Keytruda) increases the survival time of patients with advanced head and neck cancers, according to a new global study led by Yale Cancer Center (YCC). The data was published today ...
Nov 4, 2019
0
26